Hard to Treat Diseases Incorporated - HTTD - Announces: Proposed Sponsored Research and Development Agreement with the University of Colorado Health Sciences Center and the Denver Veteran's Affairs Medical Center.

Business Editors/Health/Medical Writers

DELRAY BEACH, Fla.--(BUSINESS WIRE)--May 3, 2004

Hard to Treat Diseases Incorporated (HTTD) (Pink sheets:HTDS) announced today its intention to enter into a Material Transfer Agreement and establish a Sponsored Research and Development Agreement with the University of Colorado Health Sciences Center and the Denver Veteran's Affairs Medical Center in Denver, Colorado. Scientists at the University of Colorado and the Veteran's Affairs Medical Center will work with HTTD to investigate the effects of Tubercin(R) on a variety of diseases. Tubercin(R) is a proprietary drug and patented immunostimulant for which HTTD holds the international marketing rights, except for South Korea. The Sponsored Research and Development Agreement that HTTD plans to establish with The University of Colorado and Veteran's Affairs Medical Center will follow a focused agenda to assess novel uses for Tubercin(R). It is expected that these studies will considerably expand the potential clinical applications of this substance, while focusing on the treatment of important diseases using Tubercin(R). The testing to be performed will include experiments that directly examine the effects of Tubercin(R) on various human diseases under controlled laboratory conditions. Additional studies will use specially designed cells that isolate specific steps in the process of infection, and this will enable the research team to discern the mechanism of action of Tubercin(R). White cells freshly-isolated from blood will also be used to assess Tubercin(R) activity in models of disease. These investigations of fresh human cells will provide "real life" models of disease in the presence of Tubercin(R), and the resultant data will be used to assess the potential applicability of Tubercin(R) in patient care. The Agreement with the University of Colorado Health Sciences Center and the Denver Veteran's Affairs Medical Center will have a two year term. Although these intensive studies will focus on the activity of Tubercin(R) in diseases, additional tests will explore alternative, and as yet unknown, applications for Tubercin(R). It is expected that preliminary data relevant to the use of Tubercin(R) in treating a variety of diseases will become available within the first 6 months of the investigations. Dr. Leland Shapiro heads the laboratory at the University of Colorado Health Sciences Center and Denver Veteran's Affairs Medical Center and will be the principal investigator responsible for conducting the majority of these experiments. This laboratory has a reputation for discovering novel uses for existing compounds, especially in the area of infectious diseases.

Mr. Colm J. King, the President and CEO of Hard to Treat Diseases, Inc. commented, "I'm proud to announce that Dr. Leland Shapiro will be conducting the majority of these studies. The testing and advancement of Tubercin(R) will move forward under the supervision of the most capable professionals."

Tubercin(R) is a natural substance that is derived from the external cell wall of a specific microorganism. Tubercin(R) possesses unique immunological properties that HTTD and its research partners have only just begun to explore. Although initial applications have focused on the treatment of diseases that affect the immune system, the effects of Tubercin(R) on the human body may likely extend to the treatment of a variety of diseases. In carefully controlled studies in animals and in preliminary human studies, Tubercin(R) has demonstrated remarkable safety. Should the collaborative laboratory results indicate that Tubercin(R) has activity against diseases in patients, HTTD will make a strategic decision on which clinical applications to pursue. Application for FDA approval for specific applications will be considered at that time.

Mr. King added, "HTTD has completely separated the recycling and drug testing divisions. The pending sale of the International Foam Solutions Division's assets will bring additional cash reserves into the Company and retain a 20% equity interest in the purchasing company, which has far greater potential in the environmental market. This is due to the purchasing company having the expertise, know-how, and personnel to bring the environmental product to market successfully. My goals are to aggressively advance Tubercin(R) and thereby increase the value of HTTD. I intend to keep shareholders informed and to advance HTTD as expeditiously as possible."

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.